Requirement for expert histopathological assessment of ovarian cancer and borderline tumors.
The distinction between borderline ovarian tumours (BOT) and ovarian carcinoma is made by histopathological assessment. Of 64 patients managed according to institutional BOT protocols, 27 (42%) had been referred with a diagnosis of ovarian carcinoma that was subsequently changed to BOT following histopathological review. The 70% 6-year event-free survival of the patients with a revised diagnosis was not significantly different from those who were referred with a diagnosis of BOT. This change in diagnosis is important as it avoids the need for chemotherapy for most patients and results in patients receiving appropriate information concerning prognosis. Interestingly, 24 patients (38.1%) reported a family history of epithelial cancer, a finding that has not been reported previously. Campaign
Sengupta
P S
PS
Department of Medical Oncology, Christie Hospital National Health Trust, Withington, Manchester, UK.
Shanks
J H
JH
Buckley
C H
CH
Ryder
W D
WD
Davies
J
J
Reynolds
K
K
Slade
R J
RJ
Kitchener
H C
HC
Jayson
G C
GC
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002454:Cell Differentiation; D018450:Disease Progression; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000473:pathology*; D012008:Recurrence
D000970:Antineoplastic Agents